3 ms·
continuing that quote "The current CARTs kill not just cancer cells but any B-cell, the type of white blood cell that goes wrong in leukemia. Patients are likel
by protomyth 12y ago
continuing that quote "The current CARTs kill not just cancer cells but any B-cell, the type of white blood cell that goes wrong in leukemia. Patients are likely to get injections of a protein that B-cells make, called gamma globulin, for the rest of their lives; if the treatment becomes popular there may not be enough gamma globulin to go around."
So, not scalable?
- quasque 12y agoYes, it lacks scalability because the source of the replacement immunoglobulin (antibodies) is blood donors, of which there are a limited amount.
- suby 12y agoI know nothing about this so forgive my ignorance, but could synthetic blood provide what's needed? From what I understand we're making progress with synthesizing blood. http://www.telegraph.co.uk/health/healthnews/10765132/Artificial-blood-will-be-manufactured-in-factories.html http://www.telegraph.co.uk/health/healthnews/10765132/Artifi...
- ghkbrew 12y agoPretty much no. Most synthetic blood efforts are focused on replacing the oxygen-carrying components of blood i.e. red blood cells and the hemoglobin they contain. That is what's needed in emergency settings and surgery where lack of blood flow can kill tissues in minutes. Immunoglobulins (aka antibodies) are important for preventing infection and thus long term health but they would be difficult to impossible to produce synthetically.
- asdkl234890 12y ago* Immunoglobulins (aka antibodies) are important for preventing infection and thus long term health but they would be difficult to impossible to produce synthetically.* Even with hybridomas?
- ghkbrew 12y agoYes, there are ways of producing antibodies outside the body. One could argue whether hybridomas (essentially immortalized b-cells used to produce a specific antibody) constitute truly synthetic production. I considered mentioning them, but decided it was probably more in depth answer than the GP's question really needed. Since you asked though, I don't think hybridomas really solve the difficulty of reconstituting a persons antibodies ex vivo. A healthy human has somewhere around a trillion different antibodies circulating. I would conservatively estimate that the research community has produced a few thousand different hybridomas since they were first described in 1975. The problem of scaling that or any other in vitro technique to the trillions seems unlikely to be solved. Now, I get into the domain of wild speculation. What you'd really need is a single system capable of producing a nearly unlimited variety of different antibodies. The most viable option to my mind would be a transgenic mammal (let's say a goat since it's easy to get antibodies from milk) which would produce humanized antibodies. However, given the relatively small demand for such treatments, I think any such efforts are unlikely.
- asdkl234890 12y agoCan't we use hybridoma to make immunoglobulin?
- gte910h 12y agoFriend of mine had to get gammaglobulin shots for a few years (8 or so years ago): The stuff supposedly cost about 10k a vial, because it was filtered out of the plasma of many of people per vial and put through several complicated processes to isolate and sterilize it. So...if we had considerably larger plasma donations, maybe?
- quasque 12y agoThat would help up to a point, but there also ongoing research to manufacture it using recombinant techniques - that is, genetically engineering bacteria to produce the required protein product and then purifying it out. Then your limiting factor is a reproducible manufacturing process rather than availability of human sources. This is akin to how, for example, insulin and human growth hormone are now produced; previously they also lacked scalability due to having to be sourced from cadavers. So yes right now it's not scalable, but in the future this limitation will hopefully be corrected.